TSCAN THERAPEUTICS INC. - COMMON STOCK

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

05 Nov 2024 09:15:27 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

04 Oct 2024 09:05:45 By Nasdaq GlobeNewswire

TScan Therapeutics to Participate in Upcoming Investor Conferences

29 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

12 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Updates to its Board of Directors

14 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

30 May 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

24 Apr 2024 16:05:34 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

24 Apr 2024 11:03:30 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

22 Apr 2024 17:01:23 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Closing of Upsized Public Offering

19 Apr 2024 10:05:23 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

17 Apr 2024 00:30:57 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

16 Apr 2024 16:25:22 By Nasdaq GlobeNewswire

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

16 Apr 2024 16:01:00 By Nasdaq GlobeNewswire

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

08 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

02 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

06 Mar 2024 07:00:00 By Nasdaq GlobeNewswire